These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26754331)

  • 1. An open-label, phase 2, single centre, randomized, crossover design bioequivalence study of AndroForte 5 testosterone cream and Testogel 1% testosterone gel in hypogonadal men: study LP101.
    Wittert GA; Harrison RW; Buckley MJ; Wlodarczyk J
    Andrology; 2016 Jan; 4(1):41-5. PubMed ID: 26754331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
    Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.
    Jockenhövel F; Vogel E; Kreutzer M; Reinhardt W; Lederbogen S; Reinwein D
    Clin Endocrinol (Oxf); 1996 Jul; 45(1):61-71. PubMed ID: 8796140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
    Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
    J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
    Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
    J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.
    Meikle AW; Arver S; Dobs AS; Sanders SW; Rajaram L; Mazer NA
    J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.
    Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD
    J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men--a clinical research center study.
    Wang C; Iranmanesh A; Berman N; McDonald V; Steiner B; Ziel F; Faulkner SM; Dudley RE; Veldhuis JD; Swerdloff RS
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2749-57. PubMed ID: 9709942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
    Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
    Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
    J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.
    Salehian B; Wang C; Alexander G; Davidson T; McDonald V; Berman N; Dudley RE; Ziel F; Swerdloff RS
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3567-75. PubMed ID: 8530600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men.
    Stuenkel CA; Dudley RE; Yen SS
    J Clin Endocrinol Metab; 1991 May; 72(5):1054-9. PubMed ID: 1902483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group.
    Winters SJ; Atkinson L
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):317-22. PubMed ID: 9373453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical trial of testosterone replacement therapy in hypogonadal men.
    Conway AJ; Boylan LM; Howe C; Ross G; Handelsman DJ
    Int J Androl; 1988 Aug; 11(4):247-64. PubMed ID: 3139571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men.
    Wilson DE; Meikle AW; Boike SC; Fairless AJ; Etheredge RC; Jorkasky DK
    J Clin Pharmacol; 1998 Jan; 38(1):54-9. PubMed ID: 9597560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men.
    Amory JK; Anawalt BD; Blaskovich PD; Gilchriest J; Nuwayser ES; Matsumoto AM
    J Androl; 2002; 23(1):84-91. PubMed ID: 11780927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
    Wang C; Swerdloff R; Kipnes M; Matsumoto AM; Dobs AS; Cunningham G; Katznelson L; Weber TJ; Friedman TC; Snyder P; Levine HL
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3821-9. PubMed ID: 15292312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial.
    Kühnert B; Byrne M; Simoni M; Köpcke W; Gerss J; Lemmnitz G; Nieschlag E
    Eur J Endocrinol; 2005 Aug; 153(2):317-26. PubMed ID: 16061839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men.
    Jockenhövel F; Blum WF; Vogel E; Englaro P; Müller-Wieland D; Reinwein D; Rascher W; Krone W
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2510-3. PubMed ID: 9253326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.